Group 1 - Longjian Co., Ltd. won a bid for a highway maintenance project in Heilongjiang with a contract value of 483 million yuan, accounting for 2.64% of the company's expected revenue for 2024 [1] - Transsion Holdings plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] - Good Home's controlling shareholder intends to reduce its stake by up to 2.7%, equivalent to no more than 39.4468 million shares [1][2] Group 2 - Xinhua Insurance reported a cumulative premium income of 181.973 billion yuan from January to October, representing a year-on-year growth of 17% [2][4] - Zhejiang Jiaokao is part of a consortium that plans to bid for a new urbanization project with an estimated total investment of 11.103 billion yuan [4] Group 3 - Changchun High-tech received approval for clinical trials of a vaccine for adolescents and adults [6] - XinNuoWei's application for the listing of Pertuzumab injection has been accepted, targeting HER2-positive breast cancer [8] - Dash Smart won a bid for an intelligent project at the new Huanggang Port inspection building, valued at 55.056 million yuan, which is 1.74% of its expected revenue for 2024 [8] Group 4 - Electronic City is involved in a lawsuit for debt recovery, with the amount in dispute estimated at 777 million yuan [9] - Haibo Technology signed a strategic cooperation agreement with CATL for a cumulative procurement of no less than 200 GWh of electricity from 2026 to 2028 [10] Group 5 - Renfu Pharmaceutical's HW231019 tablets have entered the second phase of clinical trials for postoperative pain relief [11] - Tonghua Dongbao received a drug registration certificate for Aspart Insulin injection from the Dominican Republic [11] Group 6 - Shaanxi Construction reported winning major projects worth a total of 1.016 billion yuan in October [12] - Fuzhou Environmental Protection plans to change its stock name to "Fuzhou Technology" [12] Group 7 - Panlong Pharmaceutical's gel patch for knee osteoarthritis has received approval for clinical trials [15] - Zhongyida's application for a specific stock issuance has been terminated by the Shanghai Stock Exchange [16] Group 8 - Zhizhong Home's controlling shareholder reduced its holdings of convertible bonds by 905,000 units, accounting for 13.51% of the total issued [19] - Haibo Co., Ltd. plans to establish a subsidiary with an investment of 1 billion yuan for high-end component projects [21] Group 9 - Caina Co. plans to use 57 million yuan of idle funds to purchase structured deposits [23] - Zhendong Pharmaceutical's new drug for acute ischemic stroke has entered the IIa phase of clinical trials [25] Group 10 - Weiman Sealing's overseas subsidiary plans to lease a factory in Saudi Arabia for 5 years at a total rent of approximately 54.039 million yuan [26] - Yiling Pharmaceutical's application for Memantine Hydrochloride has been approved for market entry [28] Group 11 - Dongfang Zhizao plans to acquire 70% of Saifu Machinery for 27.4887 million yuan [30] - JianKai Technology's actual controller intends to transfer 3% of the company's shares through inquiry [31] Group 12 - Rejing Bio plans to repurchase shares worth between 100 million and 200 million yuan [32] - Bangji Technology has decided to terminate a major asset restructuring project due to failure to reach an agreement [34] Group 13 - Huadong Pharmaceutical's application for the marketing license of a new drug has been accepted [36] - Zhonggu Logistics' shareholder plans to reduce its stake by up to 3% [38] Group 14 - Bohui Innovation's subsidiary received approval for a clinical trial of a vaccine for invasive infections [40] - Shannon Chip's shareholder pledged 0.27% of the company's shares for financing [42] Group 15 - Shanghai Petrochemical appointed a new general manager [44] - Jiaojian Co. plans to reduce the holdings of some directors and executives by up to 0.35% [46] Group 16 - Weiting Electric plans to raise no more than 300 million yuan through a private placement [47] - Zhongjin Irradiation plans to invest approximately 200 million yuan in an electronic accelerator manufacturing project [49] Group 17 - Tongxing Technology signed a framework agreement to invest 3.2 billion yuan in a sodium battery project [50] - Hongri Da plans to establish a subsidiary focused on semiconductor packaging [51] Group 18 - Shanghai Kaibao's new drug for acute ischemic stroke has received approval for clinical trials [53] - Yitong Century announced a change in its control structure, becoming a company without a controlling shareholder [55]

Core Points - JianKai Technology announced the preliminary transfer price of 76.18 yuan per share based on the inquiry subscription situation as of November 12, 2025 [1] - The transferee is prohibited from transferring the acquired shares within six months after the acquisition [1]

北京键凯科技股份有限公司 股东询价转让定价情况提示性公告 XUAN ZHAO 保证向北京键凯科技股份有限公司（以下简称"公司"）提 供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、 准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据 2025 年 11 月 12 日询价申购情况，初步确定的本次询价转让价格为 76.18 元/股。 受让方通过询价转让受让的股份，在受让后 6 个月内不得转让。 证券代码：688356 证券简称：键凯科技 公告编号：2025-038 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为 76.18 元/股。 北京键凯科技股份有限公司董事会 2025 年 11 月 13 日 1 上海分公司最终办理结果为准。 （二）本次询价转让不涉及公司控制权变更，不会影响公司治理结构和持续 经营。 特此公告。 （二）参与本次询价转让报价的机构投资者家数为 17 家，涵盖了基金管理 公司、保险公司、证券公司、私募基金管理人、合格境外投资者等专业机构投资 者。参与本次询价转让报价的机构投资 ...

Core Viewpoint - The company JianKai Technology (688356.SH) has disclosed the pricing situation for a shareholder inquiry transfer, with a preliminary transfer price set at 76.18 yuan per share based on the inquiry subscription situation as of November 12, 2025 [1] Group 1 - The total number of shares to be transferred in this inquiry transfer is 1.8195 million shares, which has been fully subscribed [1] - The preliminary determined transferees consist of 12 institutional investors [1]

Core Viewpoint - JianKai Technology announced a preliminary inquiry transfer price of 76.18 yuan per share based on the inquiry subscription situation as of November 12, 2025 [1] Group 1: Inquiry Transfer Details - A total of 17 institutional investors participated in the inquiry transfer, including fund management companies, insurance companies, securities companies, private fund managers, and qualified foreign investors [1] - The total number of shares effectively subscribed by participating institutional investors reached 3.308 million shares, resulting in an effective subscription multiple of 1.82 times [1] - The proposed transfer shares have been fully subscribed, with a preliminary determination of 12 institutional investors as the transferees, intending to acquire a total of 1.819521 million shares [1]

Core Viewpoint - The controlling shareholder and chairman of JianKai Technology (688356.SH) plans to reduce his stake by transferring 1,819,521 shares, representing 3% of the company's total equity and 12.23% of his holdings [1] Summary by Relevant Sections - **Share Reduction Details** - The share transfer will be conducted through an inquiry-based method [1] - The transfer price will not be lower than 70% of the average stock trading price over the previous 20 trading days prior to the issuance of the subscription invitation [1] - The transferee is prohibited from transferring the acquired shares within six months after the acquisition [1]

Core Viewpoint - JianKai Technology (688356.SH) announced a share transfer plan involving the transfer of 1,819,521 shares, representing 3% of its total share capital, due to the shareholder's personal funding needs [1] Group 1: Share Transfer Details - The transferring shareholder, Xuan Zhao, currently holds 14,881,610 shares, accounting for 24.54% of JianKai Technology's total share capital [1] - The share transfer will not occur through centralized bidding or block trading, and the transferee is restricted from transferring the shares for six months post-acquisition [1] - Xuan Zhao is the controlling shareholder, actual controller, chairman, and senior management of JianKai Technology, and is a U.S. national [1] Group 2: Historical Shareholding Changes - In 2022, shareholder Liu Huimin reduced their holdings by 2,643,200 shares, which is 4.41% of the total share capital, with a total cash-out of approximately 649.38 million yuan [2] - The reduction occurred between September 1, 2021, and March 16, 2022, with share prices ranging from 211.67 to 317.88 yuan per share [2] Group 3: Initial Public Offering (IPO) Information - JianKai Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 26, 2020, with an initial public offering of 15 million shares at a price of 41.18 yuan per share [3] - The total funds raised during the IPO amounted to 617.70 million yuan, with a net amount of 552.28 million yuan after expenses [3] - The company raised 23.22 million yuan more than initially planned, with funds allocated for various projects including the industrialization of medical polyethylene glycol [3]

Core Viewpoint - The announcement details a share transfer plan by major shareholder XUAN ZHAO of Beijing Jiankai Technology Co., Ltd., involving the transfer of 1,819,521 shares, representing 3% of the company's total equity, to institutional investors through a non-public inquiry transfer process [3][4]. Group 1: Share Transfer Details - The total number of shares to be transferred is 1,819,521, which accounts for 3% of Jiankai Technology's total share capital [3]. - The transfer will not occur through centralized bidding or block trading, and the shares cannot be transferred by the acquirer within six months after the acquisition [3]. - The acquirer must be an institutional investor with appropriate pricing capabilities and risk tolerance [3][8]. Group 2: Seller Information - The seller, XUAN ZHAO, is the controlling shareholder, chairman, and senior management of Jiankai Technology, holding over 5% of the company's shares [4]. - As of November 11, 2025, the seller holds 14,881,610 shares, all of which are unpledged and free from transfer restrictions [4][5]. Group 3: Pricing and Transfer Process - The minimum transfer price will be set at no less than 70% of the average trading price of Jiankai Technology's shares over the 20 trading days prior to the issuance of the subscription invitation [6]. - If the total number of valid subscriptions exceeds the number of shares available for transfer, the transfer price will be determined based on a priority system of subscription price, quantity, and time of submission [7]. Group 4: Company Status and Risks - Jiankai Technology does not have any undisclosed operational risks or circumstances that could lead to a change in control due to this share transfer [8]. - There are no other significant undisclosed matters related to the company [8].

分组1 - Midea Group announced a cash dividend distribution plan for the 2025 mid-term A-shares, distributing 5 yuan per 10 shares, totaling 3.448 billion yuan [1] - Huayuan Communication is planning a change in control and will suspend trading of its stock starting November 12, 2025, for up to two trading days [2] - Shangwei New Materials reported a significant stock price increase of 1573.52% from July 9 to November 11, 2025, but its new intelligent robot business is still in the development stage and has not generated revenue [3] 分组2 - Shannon Chip announced that shareholder Shenzhen Xinlianpu pledged 1.27 million shares, accounting for 5.55% of its holdings and 0.27% of the total share capital [4] - Tianji Co., Ltd. reported that its controlling shareholder pledged 39.965 million shares for its own production and operation, representing 64.79% of its holdings and 7.97% of the total share capital [5] - ST Zhengping completed its stock trading situation review and will resume trading on November 12, 2025, with no significant changes in its production and operation [6] 分组3 - Furi Co. reported that its subsidiary Furi New Energy is facing risks of losses despite a 47.78% year-on-year increase in revenue to 168.3981 million yuan for the first three quarters of 2025 [7] - Wentai Technology announced that major shareholders reduced their holdings by 12.4443 million shares, completing the reduction plan [8] 分组4 - Anke Biotech signed a framework agreement for exclusive agency of PA3-17 injection, a CAR-T cell therapy product, in Greater China [9] - Tongxing Technology plans to invest approximately 3.2 billion yuan in a project to produce 100,000 tons of sodium-ion battery cathode materials and 6 GWh of battery cells [10] - Redik plans to establish a joint venture for the development of robotic components, with a registered capital of 100 million yuan [11] 分组5 - Haike New Source signed a strategic cooperation agreement with Kunlun New Materials for the purchase of 596,200 tons of electrolyte solvent over three years [12] - World announced that its diamond micro-drill products for PCB processing are still in the R&D phase and have not generated revenue [13] 分组6 - Xiamen Airport reported a 1.56% year-on-year increase in passenger throughput for October [14] - New City Holdings reported a 7.65% year-on-year increase in total commercial operating revenue for October [15] - Huadong Holdings announced a 0.65% year-on-year decrease in pig sales revenue for October [15] 分组7 - Keykai Technology's controlling shareholder plans to transfer 3% of its shares [15] - Zhongyou Engineering won a joint bid for a project worth approximately 3 billion yuan in Kazakhstan [15] - Weiteng Electric plans to raise no more than 300 million yuan through a private placement for smart manufacturing projects [15]

分组1 - Midea Group announced a cash dividend distribution plan for the 2025 interim A-shares, proposing a payout of 5 yuan for every 10 shares, totaling 3.448 billion yuan [2] - Huayuan Communication is planning a change in control and will suspend trading of its stock starting November 12, 2025, for up to two trading days [3] - Shangwei New Materials reported a significant stock price increase of 1573.52% from July 9 to November 11, 2025, but its new intelligent robot business is still in the product development stage and has not yet generated revenue [4] 分组2 - Shannon Chip announced that shareholder Shenzhen Xinlianpu has pledged 1.27 million shares, accounting for 5.55% of its holdings and 0.27% of the total share capital, for financing purposes [5] - Tianji Co., Ltd. disclosed that its controlling shareholder has pledged 39.965 million shares for its own production and operation, representing 64.79% of its holdings and 7.97% of the total share capital [6] - ST Zhengping completed its stock trading situation review and will resume trading on November 12, 2025, with no significant changes in its production and operation [7] 分组3 - Furi Co., Ltd. reported that its subsidiary Furi New Energy is facing a risk of losses despite a 47.78% year-on-year increase in revenue to 168.3981 million yuan for the first three quarters of 2025 [8] - Wentai Technology announced that major shareholders have reduced their holdings by 12.4443 million shares, completing the reduction plan [9] - Anke Biotech signed a framework agreement for exclusive agency of the PA3-17 injection product in Greater China, which is a CAR-T cell therapy for certain cancers [10] 分组4 - Tongxing Technology plans to invest approximately 3.2 billion yuan in a project to produce 100,000 tons of sodium-ion battery cathode materials and 6GWh battery cells [11] - Redick is collaborating with Aoyi Technology to establish a joint venture for the development of robotic components, with a registered capital of 100 million yuan [12] - Haike New Source signed a strategic cooperation agreement with Kunlun New Materials for the purchase of 596,200 tons of electrolyte solvent over a two-year period [13] 分组5 - World announced that its diamond micro-drills for PCB processing are still in the research and testing phase, with limited revenue impact [14][15] - Huadong Holdings reported a 0.65% year-on-year decline in pig sales revenue for October [16] - Keykai Technology's controlling shareholder plans to transfer 3% of its shares through an inquiry [17]